The financials
Integra LifeSciences Holdings Corporation by the numbers
Integra LifeSciences Holdings Corporation (IART) reported revenue of $392M in Q1 2026 (quarter ended Mar 31, 2026), up 2.4% from the same quarter a year earlier. That came with a gross margin of 55% and net loss of $4.6M. For the full year FY2025, revenue was $1.64B (+1.5% year on year) and net income −$516M. Its largest product in Jun 2026 was Neurosurgery at $213M, 51% of the disclosed total, well ahead of Wound Reconstruction Solutions at 19%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $392M | $383M | +2.4% |
| Gross profit | $217M | $194M | +12% |
| Operating income | $11M | −$15M | to a profit |
| Net income | −$4.6M | −$25M | n/a |
| Diluted EPS | −$0.06 | −$0.33 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Neurosurgery | $213M | 51% |
| Wound Reconstruction Solutions | $81M | 19% |
| Surgical Instruments | $55M | 13% |
| ENT Solutions | $41M | 9.8% |
| Private Label | $28M | 6.7% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $418.8M (+6.8%)
Private Label grew +4.8% year on yearWound Reconstruction Solutions -4.1% year on year
Segment Latestquarter on quarteryear on year
- Neurosurgery$213.3M$213.3MQoQ +7.6%year on year +2.0%+7.6%+2.0%
- Wound Reconstruction Solutions$81.3M$81.3MQoQ -year on year -4.1%--4.1%
- Surgical Instruments$54.8M$54.8MQoQ -year on year +3.3%-+3.3%
- ENT Solutions$41.2M$41.2MQoQ -year on year -1.6%--1.6%
- Private Label$28.2M$28.2MQoQ -3.3%year on year +4.8%-3.3%+4.8%